Antigens, assays, and methods associated with sars-cov-2
AssigneeKREUTZ, Fernando Thome
InventorFernando Thome Kreutz
Life of this patent
Estimating the term…
Abstract
Described herein is an assay for determining immune status in a subject. The assay comprises a probe for measuring disease-specific antibodies in a sample from the subject to determine a unit score. The unit score correlates to the immune status of the subject. Methods for determining the immune status of the subject are also described.
Claims83
An assay for determining immune status in a subject, the assay comprising:
- a probe for measuring disease-specific antibodies in a sample from the subject to determine a unit score, wherein the unit score correlates to the immune status of the subject.
A method for determining immune status in a subject, the method comprising:
- measuring disease-specific antibodies in a sample;
- and
- determining a unit score based on the disease-specific antibodies measured;
- wherein the unit score correlates to the immune status of the subject.
A method for predicting the likelihood of being infected with a pathogen, the method comprising:
- measuring pathogen-specific antibodies in a sample;
- and
- determining a unit score based on the pathogen-specific antibodies measured;
- wherein the unit score predicts the likelihood of being infected with the pathogen.
A method for determining vaccination status for a disease, the method comprising:
- measuring disease-specific antibodies in a sample from a subject;
- and
- determining a unit score based on the disease-specific antibodies measured;
- wherein the unit score correlates to vaccination status.
A method for determining whether a subject should be administered an RNA vaccine against a disease, the method comprising:
- measuring disease-specific antibodies in a sample from a subject;
- and
- determining a unit score based on the disease-specific antibodies measured;
- wherein the unit score predicts whether the subject should receive the RNA vaccine.
A method for vaccinating a subject against a disease, the method comprising:
- measuring disease-specific antibodies in a sample from the subject;
- determining a unit score based on the disease-specific antibodies measured;
- wherein the unit score correlates to an immune status of the subject;
- and
- vaccinating the subject if the immune status has a predetermined unit score value.
A method for measuring vaccine efficacy, the method comprising:
- measuring disease-specific antibodies in a sample from a vaccinated subject;
- and
- determining a unit score based on the disease-specific antibodies measured;
- wherein the unit score predicts the efficacy of the vaccine.
An antigen for detecting and/or generating SARS-CoV-2 antibodies, wherein the antigen comprises the SARS-CoV-2 S1 and S2 proteins or variants thereof, wherein the S1 and S2 proteins or variants adopt a substantially native conformation.
An antigen for detecting and/or generating SARS-CoV-2 antibodies, wherein the antigen comprises a spike protein conformational epitope or variant thereof, wherein the epitope is not present in S1 or S2 alone.
An antigen comprising or consisting of the polypeptide sequence of SEQ ID NO:1:
- 1
- mfvflvllpl vssqcvnltt rtqlppaytn sftrgvyypd kvfrssvlhs tqdlflpffs
- 61
- nvtwfhaihv sgtngtkrfd npvlpfndgv yfasteksni irgwifgttl dsktqslliv
- 121
- nnatnvvikv cefqfcndpf lgvyyhknnk swmesefrvy ssannctfey vsqpflmdle
- 181
- gkqgnfknlr efvfknidgy fkiyskhtpi nlvrdlpqgf saleplvdlp iginitrfqt
- 241
- llalhrsylt pgdsssgwta gaaayyvgyl qprtfllkyn engtitdavd caldplsetk
- 301
- ctlksftvek giyqtsnfrv qptesivrfp nitnlcpfge vfnatrfasv yawnrkrisn
- 361
- cvadysvlyn sasfstfkcy gvsptklndl cftnvyadsf virgdevrqi apgqtgkiad
- 421
- ynyklpddft gcviawnsnn ldskvggnyn ylyrlfrksn lkpferdist eiyqagstpc
- 481
- ngvegfncyf plqsygfqpt ngvgyqpyrv vvlsfellha patvcgpkks tnlvknkcvn
- 541
- fnfngltgtg vltesnkkfl pfqqfgrdia dttdavrdpq tleilditpc sfggvsvitp
- 601
- gtntsnqvav lyqdvnctev pvaihadqlt ptwrvystgs nvfqtragcl igaehvnnsy
- 661
- ecdipigagi casyqtqtns prrarsvasq siiaytmslg aensvaysnn siaiptnfti
- 721
- svtteilpvs mtktsvdctm yicgdstecs nlllqygsfc tqlnraltgi aveqdkntqe
- 781
- vfaqvkqiyk tppikdfggf nfsqilpdps kpskrsfied llfnkvtlad agfikqygdc
- 841
- lgdiaardli caqkfngltv lpplltdemi aqytsallag titsgwtfga gaalqipfam
- 901
- qmayrfngig vtqnvlyenq klianqfnsa igkiqdslss tasalgklqd vvnqnaqaln
- 961
- tlvkqlssnf gaissvlndi lsrldkveae vqidrlitgr lqslqtyvtq qliraaeira
- 1021
- sanlaatkms ecvlgqskrv dfcgkgyhlm sfpqsaphgv vflhvtyvpa qeknfttapa
- 1081
- ichdgkahfp regvfvsngt hwfvtqrnfy epqiittdnt fvsgncdvvi givnntvydp
- 1141
- lqpeldsfke eldkyfknht spdvdlgdis ginasvvniq keidrlneva knlneslidl
- 1201
- qelgkyeq
- or a variant thereof.
Dependencies are inferred from the claim text.